ESTRO 2025 - Abstract Book

S1895

Clinical - Urology

ESTRO 2025

Conclusion: The addition of GEM to CDDP did not improve 2-year DFS in the management of MIBC treated with TMT. These results should be interpreted with caution due to the premature interruption of the study and an insufficient accrual rate.

Keywords: Trimodal therapy, bladder cancer

References: 1- Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long term results of a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853-9 2- Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1310-6.